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A common mutation of cholesteryl ester transfer protein gene in hemodialysis patients [2, 3] and is related to an occur-
in dialysis patients. rence of ischemic heart disease in hemodialysis patients
Background. In patients on maintenance hemodialysis, a [4] as well as in the general population.decreased concentration of high-density lipoprotein choles-
Recently, a common missense mutation, D442G (Aspterol (HDL-C) is an apparent independent risk factor for vascu-
442 to Gly), in exon 15 of the cholesteryl ester transferlar disease (VD). A common missense mutation of cholesteryl
ester transfer protein (CETP) gene, D442G (Asp442 to Gly), protein (CETP) gene has been reported in the Japanese
increases HDL-C levels, but the mutation may also diminish general population [5]. CETP mediates the transfer of
the activity of reverse cholesterol transport.
cholesteryl esters (CEs) from HDL into triglyceride-richMethods. We compared the genotype distribution of the
lipoproteins and thereby stimulates reverse cholesterolD442G polymorphism and postprandial serum lipid levels be-
tween patients with and without VD in 414 hemodialysis pa- transport [6, 7]. The D442G mutation results in markedly
tients. increased HDL-C levels [5], whereas the mutation may
Results. Serum levels of total cholesterol and HDL-C did reduce activity of reverse cholesterol transport [7].not differ in patients with the mutation [group M (1)] and
Whether this mutation affects atherosclerotic complica-without the mutation [group M (2)] and in patients with and
tions in dialysis patients with uremic dyslipidemia re-without VD. However, patients with below median HDL-C
levels (,45 mg/dl) had a significantly higher prevalence of VD mains to be clarified.
than those with above median HDL levels (26.0 vs. 15.2%,
P , 0.01). Moreover, in this low–HDL-C subgroup, group
M (1) patients had a significantly higher prevalence of VD METHODS
than group M (2) patients (54.5 vs. 24.4%, P , 0.05). In the
We examined the prevalence of VD and vascular risksubgroup, group M (1) patients with VD had higher levels of
profiles in a total of 414 unselected Japanese hemodialy-total cholesterol and a higher atherogenic index than those
without VD, whereas group M (2) patients with VD had lower sis patients (246 men and 168 women; age range of 20
levels of total cholesterol and a lower atherogenic index than to 88 years; mean of 59.0) from three dialysis centers in
those without VD. the Niigata and Fukui prefectures. All patients wereConclusions. The D442G mutation may be a risk factor for
undergoing four-hour sessions of hemodialysis threeatherosclerotic complications in dialysis patients with HDL-C
times per week, generally using high-flux membranes andlevels below 45 mg/dl. Atherogenic lipid profiles may promote
atherosclerosis in the patients with the mutation, but not in standard heparin doses for anticoagulation. The mean
those with no mutation. duration of hemodialysis treatment was 8.8 6 7.5 years.
Informed consent for study participation was obtained
from each subject.
In patients on maintenance hemodialysis, a high risk
for atherosclerotic vascular disease (VD) has been well Biochemical assays
documented [1]. A reduced concentration of high-den- Venous blood samples (serum and whole blood) were
sity lipoprotein cholesterol (HDL-C) is commonly noted collected two to three hours after meals from all dialysis
patients because total cholesterol and HDL-C levels do
not change much after a meal [8]. Serum levels of totalKey words: CEPT D442G mutation, HDL-cholesterol, hemodialysis,
vascular disease. cholesterol, triglyceride, and HDL-C were measured by
standard methods. Atherogenic index was calculated 1999 by the International Society of Nephrology
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from this formula: (total cholesterol 2 HDL-C)/HDL-C. cantly higher prevalence of VD than group M (2) pa-
tients [54.5% (6/11) vs. 24.4% (47/193), P , 0.05], al-The identification of the D442G mutation in the CETP
gene was performed by polymerase chain reaction (PCR) though the two groups did not differ in any other clinical
characteristics (data not shown). In patients with aboveusing a pair of primers as previously described by Sakai
et al [5]. median HDL-C levels (N 5 210), group M (1) patients
had a prevalence similar to that of group M (2) patients
Assessment of vascular disease [12.5% (2/16) vs. 15.5% (30/194), P 5 NS].
In the low–HDL-C (,45 mg/dl) subgroup, groupCoronary artery disease. Patients having a history of
myocardial infarction or a positive result in an exercise M (2) patients with VD had lower levels of total choles-
terol and triglyceride and a lower atherogenic index thantest, which was performed in only patients with chest
pain, were diagnosed with coronary artery diseases. those without VD (Table 1). On the other hand, in the
subgroup, group M (1) patients with VD had higherPeripheral vascular disease. Peripheral VD was diag-
nosed by diminished pulses on clinical examination com- levels of total cholesterol and triglyceride and a higher
atherogenic index than those without VD (Table 1).bined with a comparison of ankle and arm systolic blood
pressures and/or peripheral angiography. An ankle/arm Among patients with VD in the subgroup, group M (1)
patients had higher levels of total cholesterol and triglyc-index of less than 0.95 indicated the presence of periph-
eral VD. eride and a higher atherogenic index than group M (2)
patients (Table 1). Group M (2) patients (N 5 26)Cerebral vascular disease. Cerebral VD was suspected
on clinical grounds, that is, a history of rapid develop- matched for clinical characteristics with the group M (1)
patients having VD (N 5 6) had a significantly lowerment of signs of focal disturbances of cerebral function
such as hemiparesis or cerebellular ataxia. The diagnoses prevalence of VD than the group M (1) patients having
VD [42.3% (11/26) vs. 100% (6/6), P , 0.02; Table 2].were confirmed by computed tomography and/or mag-
netic resonance imaging.
A patient was considered as having a VD when at DISCUSSION
least one of these three defined VDs was present.
In this preliminary study, we found that in dialysis
patients with submedian HDL-C levels, the D442G mu-Statistical analysis
tation in the CETP gene may be an independent riskContinuous variables are expressed as the mean 6 sd.
factor for VD. This finding supported a previous reportDifferences in continuous variables between patient groups
that Japanese-American men with the D442G mutationwere assessed by a nonparametric test (Mann–Whitney
and HDL-C levels between 40 and 60 mg/dl had a higherU-test). Chi-square analysis and Fisher’s exact probabil-
prevalence of coronary heart disease than subjects with-ity test were used to assess differences in noncontinuous
out the mutation [9]. Subjects with the CETP mutationvariables between groups. Odds ratios were calculated
have been shown to have qualitative defects in the abilityusing a logistic regression analysis and were adjusted for
of HDL to participate in reverse cholesterol transport,covariates. All statistic analyses were conducted using
that is, an increase in the number of abnormal HDL-2the SPSS software program. A level of P , 0.05 (two-
particles that has less antiatherogenic effects [10] and atailed tests) was considered statistically significant.
deficiency of smaller HDL species that are involved in
cellular cholesterol efflux [6, 9]. These qualitative defects
RESULTS may predominate when the mutation carriers had a con-
siderable decrease in HDL particle number, for example,There were no significant differences in any character-
istics between patients with the mutation [group M (1), low HDL-C levels of less than 45 mg/dl. Thus, in the low–
HDL-C subgroup of this study, group M (1) patientsN 5 27] and without the mutation [group M (2), N 5
387; data not shown]. may have lower activity of reverse cholesterol transport
or less antiatherogenic effects and more susceptibility toNo significant difference in postprandial levels of total
cholesterol (157 6 39 vs. 161 6 34 mg/dl) or HDL-C atherosclerotic complications than group M (2) patients,
although HDL-C levels were comparable between the(45 6 17 vs. 48 6 18 mg/dl) was observed between pa-
tients with VD (N 5 85) and without VDs (N 5 329). two groups. However, there could be unknown genes or
other clinical factors influencing VD and associated withHowever, patients with HDL-C levels below the median
(,45 mg/dl) had a significantly higher prevalence of VD the CETP mutation.
We presented another finding that atherogenic lipidthan those with HDL-C levels above the median [26.0%
(53/204) vs. 15.2% (32/210), P , 0.05] and had an inde- profiles combined with low HDL-C levels may be posi-
tively related with VD in group M (1) but negativelypendent odds ratio of 1.82 (95% CI, 1.04 to 3.2; P , 0.05)
for VD (detailed data not shown). In this low–HDL-C related in group M (2). This finding may reflect a lower
activity of reverse cholesterol transport in group M (1)subgroup (N 5 204), group M (1) patients had a signifi-
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Table 1. Characteristics of patients with and without vascular disease in group M (1) and group M (2) for low HDL-C subgroupa
Group M (1) Group M (2)
Patients with Patients without Patients with Patients without
vascular disease vascular disease vascular disease vascular disease
(N 5 6) (N 5 5) (N 5 47) (N 5 146)
Age year 67.863.8b 56.1615.2 66.7610.3b 56.8612.4
Sex male/female 3/3 4/1 33/14 96/50
Hemodialysis duration year 5.564.8 11.467.6 5.866.2b 9.667.6
Total cholesterol mg/dl 186643c,d 139621 144633b 159632
Triglyceride mg/dl 148630b,d 72626 92644b 127660
HDL-C mg/dl 3564.6 3766.8 3566.3 3466.4
Atherogenic index 5.361.2c,e 3.961.0 4.261.3b 4.961.3
Hypertension % 6 (100%) 4 (80%) 42 (89.3%)b 101 (69.2%)
Diabetes mellitus % 2 (33.3%) 0 (0%) 21 (44.7%)b 15 (10.3%)
Smoking history % 1 (16.7%) 2 (40%) 28 (59.6%)f 58 (39.7%)
Prevalence of antilipemic drug use % 2 (33.3%) 0 (0%) 4 (8.5%) 9 (6.2%)
a Groups M(1) and M(2) indicate hemodialysis patients with and without CETP mutation, respectively. HDL-C indicates high density lipoprotein-cholesterol.
The low HDL-C subgroup consists of patients with the sub-median HDL-C levels (,45 mg/dl)
b P , 0.01 vs. patients without vascular disease in each group
c P , 0.06 vs. patients without vascular disease in group M(1)
d P , 0.01 vs. patients with vascular disease in group M(2)
e P , 0.06 vs. patients with vascular disease in group M(2)
f P , 0.05 vs. patients without vascular disease in group M(2)
Table 2. Clinical data of group M (1) patients with vascular disease and characteristic-matched group M (2)
patients in low HDL-C subgroupa
Group M (1) patients with Characteristic-matched
vascular disease group M (2) patients
(N 5 6) (N 5 26)
Age years 67.863.8 67.367.7
Sex male/female 3/3 13/13
Hemodialysis duration year 5.564.8 5.466.2
Serum cholesterol mg/dl 186643 174625
Triglyceride mg/dl 148630 137662
HDL-C mg/dl 3565 3266
Atherogenic index 5.361.2 5.660.9
Hypertension % 6 (100%) 26 (100%)
Diabetes mellitus % 2 (33.3%) 9 (34.6%)
Smoking history % 1 (16.7%) 7 (26.9%)
Prevalance of antilipemic drug use % 2 (33.3%) 2 (7.7%)
Prevalence of vascular disease % 6 (100%)b 11 (42.3%)
a Groups M(1) and M(2) indicate hemodialysis patients with and without the CETP mutation, respectively. HDL-C indicates high density lipoprotein-cholesterol.
The low HDL-C subgroup consists of patients with the sub-median HDL-C levels (,45 mg/dl).
b P , 0.02 vs. characteristic-matched group M(2) patients
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